Administration of Autologous Mesenchymal Cells for the Treatment of Arthritis

Author(s): Chadwick Prodromos*, Tobias Rumschlag

Journal Name: Current Stem Cell Research & Therapy

Volume 16 , Issue 8 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Injection of autologous mesenchymal stem cells (AMSCs) as stromal vascular fraction, culture expanded adipose derived stem cells, minimally manipulated fat graft, bone marrow aspirate or cultured bone marrow MSCs, for osteo- and inflammatory arthritis have shown good clinical efficacy in many studies. Questions have been raised as to their safety despite no evidence known to us that they are unsafe when used this way. We hypothesized that AMSC injections are completely safe for the treatment of arthritis.

Methods: A PubMed literature search was performed to identify adverse events specifically related to the injection of autologous mesenchymal or hematopoietic stem cells into arthritic joints or intravenously.

Results: 2,011 reported injections were found. No stem cell specific adverse events were identified. Specifically no infections, tumorigenesis, or chondrolysis from collagenase were found.

Conclusion: Intra-articular injection of autologous mesenchymal stem cells for the treatment of arthritis is completely safe with no stem cell specific adverse events yet documented, and no increased risk compared with other traditional treatments for arthritis.

Keywords: Mesenchymal stem cell, stromal vascular fraction, arthritis, osteoarthritis, adverse event, collagenase.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 8
Year: 2021
Published on: 24 February, 2021
Page: [931 - 938]
Pages: 8
DOI: 10.2174/1574888X16666210224145104
Price: $65

Article Metrics

PDF: 514